U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C13H16N3O4S.Mg
Molecular Weight 645.003
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METAMIZOLE MAGNESIUM

SMILES

[Mg++].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2.CN(CS([O-])(=O)=O)C3=C(C)N(C)N(C3=O)C4=CC=CC=C4

InChI

InChIKey=NHMUJYOBLYTIKO-UHFFFAOYSA-L
InChI=1S/2C13H17N3O4S.Mg/c2*1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11;/h2*4-8H,9H2,1-3H3,(H,18,19,20);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula C13H16N3O4S
Molecular Weight 310.349
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Mg
Molecular Weight 24.305
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Dipyrone, also known as Metamizole (INN), is an ampyrone sulfonate analgesic, antispasmodic and antipyretic. It was withdrawn from US market in 1977 on the basis of reports of agranulocytosis. Depyrone is still used to treat severe and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. Mechanism of action of dipyrone is complex. It is believed that dipyrone exerts its action by inhibiting COX-3, and activates opioid and cannabioid systems either itself, or by products of its metabolic degradation.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23219|||Q5T7T7
Gene ID: 5742.0
Gene Symbol: PTGS1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NEURALGIN

Approved Use

Severe and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states.
Primary
OPTALGIN

Approved Use

Optalgin Injection, by intramuscular administration, is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.
PubMed

PubMed

TitleDatePubMed
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
1984
Modifying potential of thirty-one chemicals on the short-term development of gamma-glutamyl transpeptidase-positive foci in diethylnitrosamine-initiated rat liver.
1984 Oct
Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study.
1986 Oct 3
Octreotide dependency and headache: a case report.
1994 Aug
Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia.
1996 Jun
Use of dipyrone during pregnancy and risk of Wilms' tumor. Brazilian Wilms' Tumor Study Group.
1996 Sep
Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action.
1998 Mar 26
Modifying effects of a mixture of acetaminophen, aspirin, dipyrone and ethenzamide on a multiorgan initiation model and its carcinogenicity in male F344 rats.
1999 Jan 8
Urticaria induced by meperidine allergy.
2000 Mar
Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucinations.
2001 Dec
Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test.
2002 Dec
[Postoperative analgesia with tramadol and metamizol. Continual infusion versus patient controlled analgesia].
2003 Jan
[Multifocal brain haemorrhage associated with migraine and medication abuse].
2003 Nov 1-15
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam.
2004 Jun
Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention.
2005 Dec
Lack of effect of naltrindole on the spinal synergism of morphine and non-steroidal anti-inflammatory drugs (NSAIDS).
2009 Jun
Patents

Sample Use Guides

Dipyrone was administered orally, as subcutaneous and intramuscular injections (daily dose 0.25-1 g as 50% solution), or by intravenous injection.
Route of Administration: Other
Cyclooxygenase activity was measured by the formation of PGE2 after exposure to exogenous 30 μM acid for 10 min. Dipyrone inhibited COX-1 with IC50 350 uM, and COX-3 with IC50 of 52 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:30:19 GMT 2023
Edited
by admin
on Fri Dec 15 18:30:19 GMT 2023
Record UNII
MS15642725
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METAMIZOLE MAGNESIUM
WHO-DD  
Common Name English
METHANESULFONIC ACID, 1-((2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO)-, MAGNESIUM SALT (2:1)
Common Name English
((2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO)METHANESULFONIC ACID MAGNESIUM SALT
Common Name English
DIPYRONE MAGNESIUM SALT [MI]
Common Name English
Metamizole magnesium [WHO-DD]
Common Name English
DIPYRONE MAGNESIUM
Systematic Name English
METHANESULFONIC ACID, ((2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO)-, MAGNESIUM SALT
Common Name English
METHANESULFONIC ACID, ((2,3-DIMETHYL-1-PHENYL-5-OXO-3-PYRAZOLIN-4-YL)METHYLAMINO)-, MAGNESIUM SALT
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID60977067
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
CAS
6150-97-6
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
MESH
C024864
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
FDA UNII
MS15642725
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
MERCK INDEX
m4660
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
228-161-4
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
DRUG BANK
DBSALT002439
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
EVMPD
SUB03189MIG
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
RXCUI
236464
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY RxNorm
SMS_ID
100000090116
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
PUBCHEM
10326858
Created by admin on Fri Dec 15 18:30:19 GMT 2023 , Edited by admin on Fri Dec 15 18:30:19 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY